Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial

BMJ Open. 2020 Jul 22;10(7):e038555. doi: 10.1136/bmjopen-2020-038555.

Abstract

Introduction: There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors.

Objective: To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression.

Method: This randomised controlled open-labelled trial will involve 200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians' review. The primary outcome is the time to diagnosis of COVID-19.

Ethics and dissemination: Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals.

Keywords: infection control; telemedicine; virology.

Publication types

  • Clinical Trial Protocol
  • Randomized Controlled Trial

MeSH terms

  • Artificial Intelligence*
  • Betacoronavirus
  • Blood Gas Monitoring, Transcutaneous
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Cloud Computing
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / physiopathology
  • Early Diagnosis
  • Heart Rate
  • Hong Kong
  • Humans
  • Mobile Applications*
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / physiopathology
  • Quarantine*
  • Respiratory Rate
  • SARS-CoV-2
  • Skin Temperature
  • Smartphone*
  • Telemedicine
  • Wearable Electronic Devices*